Discoveries made when biology meets computational sciences are revolutionising the landscape of life sciences and healthcare. Computational biology and bioinformatics are driving this transformation helping researchers analyse vast amounts of ...
Read MoreVANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most common form of precancer, with over 40 ...
Read MoreLONDON, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- London Research & Pharmaceuticals has recently publicized data about its lead compound LRP-661 or Cannabidiol sulphate (CBDS), highlighting its safety, efficacy, bioavailability, and ...
Read MoreKELOWNA, British Columbia , December 4, 2016 /PRNewswire/ -- Marapharm symbols: United States (OTCQB: MRPHF), Canada - ( CSE: MDM ), Germany - (FSE:2M0) Marapharm Ventures Inc. ("Marapharm") announces that it is paying the ...
Read More- New analysis of GLORIA™-AF Registry Program includes data from nearly 3,000 patients across the world RIDGEFIELD, Conn. , Dec. 4, 2016 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a new analysis ...
Read MoreWeb-based software tool by SKILLS Global supports learning of children and adolescents with autism WOODLAND HILLS, Calif. , Dec. 4, 2016 /PRNewswire/ -- California-based software company SKILLS Global has won the Gold award for "Most ...
Read More- Analysis of clinical trial efficacy results and estimated factor IX levels suggests that patients who maintain factor IX activity levels above 5 and 10 percent have significantly reduced bleeding risk SAN DIEGO , Dec. 3 , 2016 ...
Read More89% of study patients, including those with high-risk CLL/SLL, responded to therapy SAN DIEGO AND RARITAN, N.J. , Dec. 3, 2016 /PRNewswire/ -- Today, Janssen Research & Development, LLC (Janssen) announced the longest follow-up results ...
Read More--At ASH Meeting, CHOP Researchers Report on Global Multicenter Trial and Pilot Trial of Innovative Leukemia Treatments-- ...
Read More- Nearly nine out of 10 patients (89%) with CLL/SLL achieve complete or partial response at five-year analysis 1 O'Brien S, et al. Five-year experience with single-agent ibrutinib in patients with previously untreated and ...
Read MoreSubscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2024
Careers